๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

25 recruiting trials

for Myasthenia Gravis (MG)

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases NCT07470151NA1 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: EVM18001 Injection The EXPLORE MG Registry for Myasthenia Gravis NCT03792659n/a1 site๐Ÿ“ New Haven Yale University ยท Tests: Blood Sample Draw MuSK Myasthenia 1000 Study NCT06259071n/a1 site๐Ÿ“ Washington D.C. George Washington University Capturing Key MG-symptoms Using Smartphone Recordings. NCT06743490n/a2 sites๐Ÿ“ Leiden๐Ÿ“ Leiden Leiden University Medical Center Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG) NCT07413835NA1 site๐Ÿ“ Xuzhou The Affiliated Hospital of Xuzhou Medical University ยท Tests: HN2302 Injection ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis NCT07673627Phase 28 sites๐Ÿ“ Carlsbad๐Ÿ“ Miami๐Ÿ“ Las Vegas argenx ยท Tests: Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis NCT06193889Phase 2, Phase 322 sites๐Ÿ“ Los Angeles๐Ÿ“ Orange๐Ÿ“ Palo Alto Kyverna Therapeutics ยท Tests: Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101 Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis NCT06909253n/a11 sites๐Ÿ“ Bydgoszcz๐Ÿ“ Gdansk๐Ÿ“ Katowice AstraZeneca ยท Tests: Ravulizumab Zilucoplan for Severe gMG Exacerbations NCT07215949Phase 33 sites๐Ÿ“ Tampa๐Ÿ“ Kansas City๐Ÿ“ Columbus Miriam Freimer ยท Tests: Zilucoplanยฎ PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis NCT06607627Phase 313 sites๐Ÿ“ Washington D.C.๐Ÿ“ Norfolk๐Ÿ“ Joinville Alexion Pharmaceuticals, Inc. ยท Tests: Gefurulimab CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases NCT07337785EARLY Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning Feasibility of Remote Monitoring of Patients With Myasthenia Gravis NCT07787247n/a1 site๐Ÿ“ Washington D.C. George Washington University RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis NCT06359041Phase 1, Phase 217 sites๐Ÿ“ Orange๐Ÿ“ Sacramento๐Ÿ“ San Francisco Cabaletta Bio ยท Tests: CABA-201, CABA-201 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis NCT07294170n/a37 sites๐Ÿ“ Carlsbad๐Ÿ“ Miami๐Ÿ“ Miami argenx ยท Tests: Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS Myasthenia Gravis Foundation of America Global MG Patient Registry NCT06617741n/a1 site๐Ÿ“ Westborough Myasthenia Gravis Foundation of America The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis NCT05564936NA19 sites๐Ÿ“ Aurora๐Ÿ“ Jacksonville๐Ÿ“ Bloomington Ad scientiam ยท Tests: ME&MG mobile application A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) NCT07673744Phase 26 sites๐Ÿ“ Colorado Springs๐Ÿ“ Colorado Springs๐Ÿ“ Clearwater TG Therapeutics, Inc. ยท Tests: Ublituximab, Placebo Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases NCT06626919Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Orange๐Ÿ“ Palo Alto Kite, A Gilead Company ยท Tests: anito-cel, Cyclophosphamide, Fludarabine A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders NCT06680037Phase 18 sites๐Ÿ“ La Jolla๐Ÿ“ Ann Arbor๐Ÿ“ Omaha TG Therapeutics, Inc. ยท Tests: Azercabtagene zapreleucel (azer-cel) AXIS MG Patient Registry NCT07761026n/a1 site๐Ÿ“ Framingham Autoimmune Neurology Alliance Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis NCT06967480n/a23 sites๐Ÿ“ Bergamo๐Ÿ“ Bologna๐Ÿ“ Bologna Alexion Pharmaceuticals, Inc. ยท Tests: Ravulizumab Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. NCT07526493Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: Universal CD19 CAR-ฮณฮดT Cell Injection, Cyclophosphamide, Fludarabine Vitaccess Real MG Registry NCT06064461n/a8 sites๐Ÿ“ Orange๐Ÿ“ O'Fallon๐Ÿ“ Lexington Vitaccess Ltd ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod NCT07284420Phase 233 sites๐Ÿ“ Carlsbad๐Ÿ“ Miami๐Ÿ“ Tampa argenx ยท Tests: Efgartigimod IV, Empasiprubart IV
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy